What is HC Wainwright’s Estimate for RARE FY2025 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Stock analysts at HC Wainwright dropped their FY2025 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a research note issued on Monday, January 5th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of ($5.26) per share for the year, down from their previous estimate of ($4.85). HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2025 earnings at ($0.71) EPS, Q1 2026 earnings at ($1.63) EPS, Q2 2026 earnings at ($1.40) EPS, Q3 2026 earnings at ($1.30) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($5.32) EPS.

RARE has been the subject of a number of other reports. Wells Fargo & Company decreased their target price on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research report on Tuesday, December 30th. Leerink Partners cut their price objective on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Truist Financial reduced their price objective on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, October 8th. Finally, Robert W. Baird reduced their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Sixteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $72.29.

Ultragenyx Pharmaceutical Trading Down 2.5%

Shares of NASDAQ:RARE opened at $22.54 on Wednesday. The stock has a market cap of $2.17 billion, a PE ratio of -3.79 and a beta of 0.15. The stock’s fifty day simple moving average is $32.33 and its two-hundred day simple moving average is $31.51. Ultragenyx Pharmaceutical has a 1-year low of $18.41 and a 1-year high of $46.50.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative net margin of 91.95% and a negative return on equity of 414.17%. The firm had revenue of $159.93 million for the quarter, compared to the consensus estimate of $167.42 million. During the same period last year, the company posted ($1.40) EPS. The business’s revenue was up 14.6% compared to the same quarter last year.

Institutional Trading of Ultragenyx Pharmaceutical

Several large investors have recently modified their holdings of the business. Parallel Advisors LLC lifted its holdings in Ultragenyx Pharmaceutical by 1,061.9% in the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 669 shares during the period. Assetmark Inc. raised its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,024 shares in the last quarter. Huntington National Bank raised its holdings in shares of Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 393 shares in the last quarter. Danske Bank A S purchased a new stake in Ultragenyx Pharmaceutical in the third quarter worth $39,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in Ultragenyx Pharmaceutical in the second quarter valued at $55,000. 97.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,081 shares of Ultragenyx Pharmaceutical stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total transaction of $112,086.78. Following the completion of the sale, the chief financial officer owned 95,146 shares of the company’s stock, valued at $3,461,411.48. The trade was a 3.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 11,108 shares of company stock worth $365,262. Company insiders own 5.50% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.